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Abstract 
Background: Many thiourea derivatives have exhibited biological activities including anticancer activity through 
several mechanisms. On the other hand, benzenesulfonamide derivatives have proven to be good anticancer agents. 
Hybrids of both moieties could be further developed to explore their biological activity as anticancer.
Results: Novel series of thioureidobenzenesulfonamides incorporating miscellaneous biologically active moieties 
3–17 were designed and synthesized utilizing 4‑isothiocyanatobenzenesulfonamide 2 as strategic starting material. 
The structures of the newly synthesized compounds were established on the basis of elemental analyses, IR, 1H‑NMR, 
13C‑NMR and mass spectral data. All the newly synthesized compounds were evaluated for their in vitro anticancer 
activity against various cancer cell lines. Most of the synthesized compounds showed good activity, especially com‑
pounds 3, 6, 8, 9, 10, 15 and 16 which exhibited good activity higher than or comparable to the reference drugs, 
DCF and Doxorubicin, except breast cancer line. As a trial to suggest the mechanism of action of the active com‑
pounds, molecular docking on the active site of mitogen kinase enzyme (MK‑2) was performed and good results were 
obtained especially for compound 3.
Conclusion: Compounds 3, 6, 8, 9, 10, 15 and 16 may represent good candidates for further biological investiga‑
tions as anticancer agents. Their cytotoxic activity could be due to their action as MK‑2 enzyme inhibitors.
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Background
Various types of cancer are now considered as the sec-
ond cause of death after cardiovascular disorders [1]. 
The inability of the present anticancer chemotherapeutic 
agents to discriminate between normal cells and cancer 
cells comprises the biggest challenge for successful can-
cer treatment [2]. Serious side effects of anticancer chem-
otherapeutic agents limit their usage and in many cases 
surgery or radiotherapy replace them [3]. The continuous 
seek for safer and more effective anticancer agents is still 
a major goal for medicinal chemists.
Thiourea is a versatile synthetic block for the synthe-
sis of a wide variety of new organic compounds with 
biological activity including antimicrobial, antifungal, 
antidiabetic, antimalarial, anti HIV and CNS active drugs 
[4–11]. Many of aryl thiourea derivatives have applica-
tions in medicine, industry and agriculture [12–15]. 
Thiourea was incorporated in many tyrosine kinase 
inhibitors because of its ability to form powerful hydro-
gen bonds in the ATP binding pocket of the enzymes 
[16]. The thiourea derivative YH345 A has shown strong 
protein farnesyl transferase inhibition activity [17]. Also 
several heterocyclic thiourea derivatives have shown 
strong DNA topoisomerase inhibitory activity [18].
On the other hand, sulfonamide derivatives posses a 
wide range of biological activity including antibacterial, 
anticonvulsant, anti-inflammatory and anticancer activ-
ity [19–22]. The mechanism of anticancer activity may 
involve a wide range of different mechanisms, such as 
cell cycle arrest in the G1 phase [23] and inhibition of 
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carbonic anhydrase [24], histone deacetylases (HDACs) 
[25], methionine amino peptidases (MetAPs) [26], matrix 
metalloproteinase (MMPs) [27], nicotinamide adenine 
dinucleotide (NADH) oxidase [28], cyclin-dependent-
kinase (CDK) [29], binding to β-Tubulin, and disruption 
of microtubule assembly [30]. Indisulam (E7070) B is an 
example of an anticancer agent that contains sulfonamide 
moiety [31].
Based on the previous facts and as a continuation of 
our previous work in the seek of novel anticancer agents 
[32–38], we herein report the synthesis and biological 
evaluation of new sulfonamide thiourea derivatives 3–17 
presented by general structure C as hybrid molecules of 
benzensulfonamide and thiourea moieties as anticancer 
agents. Molecular docking of the active newly synthe-
sized compounds was performed on the active site of 
mitogen activated kinase enzyme (MK-2) in a trial to sug-
gest a mechanism of action for their cytotoxic activity.
Results and discussion
Chemistry
The aim of this work was to design and synthesize a new 
series of thioureidobenzenesulfonamide derivatives hav-
ing miscellaneous biologically active moieties to evaluate 
their anticancer activity. Thus, interaction of 4-isothiocy-
anatobenzenesulfonamide 2 with several amines in dry 
N,N-dimethylformamide containing triethlyamine as cat-
alyst afforded the corresponding thioureidobenzenesul-
fonamude derivatives 3–17 (Schemes  1 and 2). The 
structures of the obtained compounds were established 
on the basis of elemental analyses and spectral data.IR 
spectra of compounds 3–17 showed the absence of 
N=C=S group and presence absorption bands for (NH), 
(CH arom.), (CH aliph.), (C=S) and (SO2). 1H-NMR 
spectra of compounds 3–17 exhibited a singlets at 7.8–
13.8 ppm assigned to 2NH groups of thiourea which were 
exchanged upon duetration.IR spectrum of compound 3 
showed the characteristic bands at 3312, 3214  cm−1 
(NH), 3099  cm−1 (CH arom.), 2202  cm−1 (C≡N), 
1655  cm−1 (C=O), 1387, 1157  cm−1 (SO2), 1250  cm−1 
(C=S). 1H-NMR spectrum of compound 3 exhibited a 
triplet signal at 0.8 ppm due to CH3, a multiplet at 1.2–
1.4  ppm due to 5CH2, a mutiplet at 3.3  ppm due to 
NHCH2 and singlets at 9.3 and 10.4  ppm assigned to 
2NH groups which were exchangeable with D2O. Mass 
spectrum of compound 3 revealed a molecular ion peak 
m/z at of 329 (M+) (14.41) with a base peak appeared at 
155 (100). 13C-NMR spectrum of compound 3 exhibited 
signals at 177.4 ppm assigned to (C=S). IR spectrum of 
compound 4 showed the characteristic bands at 
3363 cm−1 (OH), 3280, 3143 cm−1 (NH, NH2), 3090 cm−1 
(CH arom.), 1393, 1182  cm−1 (SO2), 1274  cm−1 (C=S). 
1H-NMR spectrum of compound 4 exhibited signals at 
10.2, 11.4 attributed to 2NH groups and 13.1  ppm 
assigned to OH group which exchangeable with D2O. 
Mass spectrum of compound 4 revealed a molecular ion 
peak m/z at of 323 (M+) (9.03) with a base peak appeared 
at 91 (100). 13C-NMR spectrum of compound 4 showed 
signals at 180.1  ppm assigned to (C=S).IR spectrum of 
compound 5 revealed the characteristic bands at 3317, 
3254, 3173  cm−1 (NH, NH2), 3100  cm−1 (CH arom.), 
2963, 2938, 2829  cm−1 (CH aliph.), 1363, 1156  cm−1 
(SO2), 1259  cm−1 (C=S). 1H-NMR spectrum of com-
pound 5 exhibited singlet at 3.9  ppm attributed to 
3OCH3 groups and singlet at 9.8 ppm assigned to 2NH 
groups, which exchangeable with D2O. Mass spectrum of 
compound 5 revealed a molecular ion peak m/z at of 367 
(M+) (17.8) with a base peak appeared at 76 (100). 13C-
NMR spectrum of compound 5 exhibited signals at 
179.3 ppm assigned to (C=S).IR spectrum of compound 
6 showed the characteristic bands at 3353, 3243, 
3171  cm−1 (NH, NH2), 3009  cm−1 (CH arom.), 1340, 
1161 cm−1 (SO2), 1290 cm−1 (C=S). 1H-NMR spectrum 
of compound 6 revealed singlet at 10.3 ppm assigned to 
2NH groups, which exchangeable with D2O. Mass spec-
trum of compound 6 exhibited a molecular ion peak m/z 
at of 366 (M+) (15.8) with a base peak appeared at 133 
(100). 13C-NMR spectrum of compound 6 exhibited sin-
glet at 180.1  ppm assigned to (C=S). IR spectrum of 
compound 7 exhibited the characteristic bands at 3325, 
3241  cm−1 (NH, NH2), 3100  cm−1 (CH arom.), 1331, 
1156 cm−1 (SO2), 1241 cm−1 (C=S). 1H-NMR spectrum 
of compound 7 showed singlet at 9.5  ppm assigned to 
2NH groups, which exchangeable with D2O. Mass spec-
trum of compound 7 revealed a molecular ion peak m/z 
at of 351 (M+) (34.64) with a base peak appeared at 93 
(100). 13C-NMR spectrum of compound 7 showed signal 
at 180.6  ppm assigned to (C=S). IR spectrum of com-
pound 8 exhibited the characteristic bands at 3384, 3348, 
3206  cm−1 (NH, NH2), 3003  cm−1 (CH arom.), 1377, 
1185 cm−1 (SO2), 1294 cm−1 (C=S). 1H-NMR spectrum 
of compound 8 showed singlet at 7.8 ppm attributed to 
2NH groups, which exchangeable with D2O. Mass spec-
trum of compound 8 exhibited a molecular ion peak m/z 
at of 365 (M+) (18.42) with a base peak appeared at 135 
(100). 13C-NMR spectrum of compound 8 showed signal 
at 161.1 ppm attributed to (C=S). IR spectrum of com-
pound 9 revealed the characteristic bands at 3434, 
3354  cm−1 (NH, NH2), 3100  cm−1 (CH arom.), 2997, 
2906, 2851 (CH aliph.), 1396, 1186 (SO2), 1282 (C=S). 
1H-NMR spectrum of compound 9 exhibited multiplet at 
1.9 ppm due to 6CH2, a multiplet at 2.2–2.4 due to 3CH 
and singlet at 11.4  ppm due to 2NH groups, which 
exchangeable with D2O. Mass spectrum of compound 9 
exhibited a molecular ion peak m/z at of 366 (M+) (9.32) 
with a base peak appeared at 154 (100). 13C-NMR 





























































Scheme 1 Synthesis of compounds 1–9










































































Scheme 2 Synthesis of compounds 10–17
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spectrum of compound 9 showed singlet at 179.9  ppm 
due to (C=S). IR spectrum of compound 10 showed the 
characteristic bands at 3359, 3257, 3143 cm−1 (NH, NH2), 
3031  cm−1 (CH arom.), 2954, 2851  cm−1 (CH aliph.), 
1594  cm−1 (C=N), 1381, 1186  cm−1 (SO2), 1296  cm−1 
(C=S). 1H-NMR spectrum of compound 10 revealed sin-
glets at 10.2 and 13.0  ppm assigned to 2NH groups, 
which exchangeable with D2O. Mass spectrum of com-
pound 10 showed a molecular ion peak m/z at of 393 
(M+) (16.9) with a base peak appeared at 162 (100). 13C-
NMR spectrum of compound 10 showed singlet at 
180.0  ppm attributed to (C=S). IR spectrum of com-
pound 11 revealed the characteristic bands at 3410, 3334, 
3195 (NH, NH2), 3069 (CH arom.), 2974, 2925, 2843 (CH 
aliph.), 1595 (C=N), 1393, 1123 (SO2), 1256 (C=S). 1H-
NMR spectrum of compound 11 revealed a triplet at 1.3 
due to CH3, a quartet at 4.0 ppm due to CH2 and a singlet 
at 10.3 and 11.2  ppm due to 2NH groups, which 
exchangeable with D2O. Mass spectrum of compound 11 
exhibited a molecular ion peak m/z at of 409 (M+) (1.85) 
with a base peak appeared at 156 (100). 13C-NMR spec-
trum of compound 11 revealed singlet at 180.1  ppm 
assigned to (C=S). IR spectrum of compound 12 revealed 
the characteristic bands at 3384, 3261, 3165 (NH, NH2), 
3097 (CH arom.), 1595 (C=N), 1331, 1185 (SO2), 1252 
(C=S). 1H-NMR spectrum of compound 12 exhibited 
singlet at 10.5 and 12.0 ppm due to 2NH groups, which 
exchangeable with D2O. Mass spectrum of compound 12 
exhibited a molecular ion peak m/z at of 409 (M+) (13.43) 
with a base peak appeared at 178 (100). 13C-NMR spec-
trum of compound 12 showed singlet at 179.9  ppm 
assigned to (C=S). IR spectrum of compound 13 revealed 
the characteristic bands at 3326, 3175 (NH, NH2), 3088 
(CH arom.), 1572 (C=N), 1356, 1192 (SO2), 1211 (C=S). 
1H-NMR spectrum of compound 13 exhibited singlet at 
12.4 ppm. due to 2NH groups, which exchangeable with 
D2O. Mass spectrum of compound 13 exhibited a molec-
ular ion peak m/z at of 388 (M+) (11.81) with a base peak 
appeared at 157 (100). 13C-NMR spectrum of compound 
13 showed singlet at 178.6 ppm attributed to (C=S). IR 
spectrum of compound 14 showed the characteristic 
bands at 3378, 3240, 3155 (NH, NH2), 3100 (CH arom.), 
1601 (C=N), 1346, 1199 (SO2), 1270 (C=S). 1H-NMR 
spectrum of compound 14 revealed singlets at 11.3, 
13.0  ppm attributed to 2NH groups. Mass spectrum of 
compound 14 showed a molecular ion peak m/z at of 309 
(M+) (12.83) with a base peak appeared at 79 (100). 13C-
NMR spectrum of compound 14 showed singlet at 
179.0  ppm attributed to (C=S). IR spectrum of com-
pound 15 revealed the characteristic bands at 3413, 3354, 
3152 (NH, NH2), 3083 (CH arom.), 2982, 2935, 2831 (CH 
aliph.), 1351, 1159 (SO2), 1264 (C=S). 1H-NMR spectrum 
of compound 15 exhibited multiplet at 1.8–2.8 ppm due 
to 4CH2 and singlet at 9.0 ppm due to 2NH groups. Mass 
spectrum of compound 15 exhibited a molecular ion 
peak m/z at of 361 (M+) (26.34) with a base peak 
appeared at 177 (100). 13C-NMR spectrum of compound 
15 showed singlet at 181.5  ppm assigned to (C=S). IR 
spectrum of compound 16 revealed the characteristic 
bands at 3373, 3246, 3164 (NH, NH2), 3077 (CH arom.), 
1595 (C=N), 1365, 1150 (SO2), 1293 (C=S). 1H-NMR 
spectrum of compound 16 exhibited singlet at 10.8 ppm. 
attributed to 2NH groups, which exchangeable with D2O. 
Mass spectrum of compound 16 exhibited a molecular 
ion peak m/z at of 358 (M+) (17.53) with a base peak 
appeared at 156 (100). 13C-NMR spectrum of compound 
16 showed singlet at 178.6 ppm attributed to (C=S). IR 
spectrum of compound 17 revealed the characteristic 
bands at 3363, 3218, 3154 (NH, NH2), 3034 (CH arom.), 
2943, 2836 (CH aliph.), 1590 (C=N), 1324, 1154 (SO2), 
1241 (C=S). 1H-NMR spectrum of compound 17 exhib-
ited singlets 10.1 and 13.8  ppm. attributed to 2NH 
groups, which exchangeable with D2O. Mass spectrum of 
compound 17 exhibited a molecular ion peak m/z at of 
372 (M+) (21.22) with a base peak appeared at 141 (100). 
13C-NMR spectrum of compound 17 showed singlet at 
179.3 ppm attributed to (C=S). 
In‑vitro anticancer evaluation
The synthesized compounds were evaluated for their 
in  vitro anticancer activity against human lung cancer 
cell line (A549-Raw), cervical (Hela) cancer cell line, 
colorectal cell line (Lovo) and breast cancer cell line 
(MDA-MB231) using 2′7′dichlorofluorescein (DCF) and 
Doxorubicin as reference drugs in this study. The rela-
tionship between surviving fraction and drug concentra-
tion was plotted to obtain the survival curve of cancer 
cell lines. The response parameter calculated was the IC50 
value, which corresponds to the concentration required 
for 50  % inhibition of cell viability. The results are pre-
sented in Table 1.
Regarding the cytotoxic activity on lung cancer cell line 
(A549), compounds 2, 3, 6, 8, 9, 15 and 16 were active 
with IC50 ranging between 29.12 and 114.28 µg ml−1. The 
most active compound was the n-heptane thiourea deriv-
ative 3. In case of cervical cancer cell line (Hela), com-
pounds 3, 6, 8, 9, 10 and 15 were active with IC50 ranging 
between 35.63 and 93.42 µg ml−1. The most active com-
pounds was again the n-hepatne thiourea derivative 3.
For the colorectal cell line (Lovo), compounds 2, 3, 8, 9 
and 10 were active with IC50 ranging between 39.83 and 
148.33 µg ml−1 and once again the most active compound 
was n-hepatne thiourea derivative 3. Finally, the activity 
on breast cancer cell line (MDA-MB231) was exhibited 
by compounds 3, 6, 8, 9, 10, 15 and 16 with IC50 ranging 
between 26.28 and 69.04 µg ml−1 with less activity than 
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Doxorubicin. The same compound (n-hepatne thiourea 
derivative 3) was the most active compound.
Structure activity relationship
In a closer look to the biological results we can see 
that: the thiourea derivatives 3, 6, 8, 9, 10, 15 and 16 
were the active compounds on most of the cell lines 
while the rest of the compounds were inactive. It was 
obvious that incorporating an n-heptane aliphatic 
substitution as in compound 3 gave the most activity 
on all cell line. This activity was reduced upon replac-
ing this substituent with another tricyclic aliphatic one 
as in compound 9. In case of aromatic substitution 
the activity was retained but markedly decreased as in 
the 2-methyl-6-nitrophenyl thiourea derivative 6, the 
3-benzo[d][1,3]dioxol-5-ylmethyl thiourea derivative 8, 
the 3-(5,6-dimethylbenzo[d]thiazol-2-yl)thiourea deriv-
ative 10, the tetrahydronaphthalen derivative 15 and the 
quinoline derivative 16.
Comparing compound 3 which was the most active 
compound among the newly synthesized compounds 
with the reference drug Doxorubicin we can see that: 
compound 3 was more active that Doxorubicin as cyto-
toxic agents on lung cancer cell line, Hella cells and colo-
rectal cancer cells with IC50 value of 29.12, 35.63 and 
39.83  µg  ml−1, respectively. However, in case of breast 
cancer cell line compound 3 was less active than Doxoru-
bicin with IC50 value of 26.28 µg ml−1.
Molecular docking
Mitogen-activated protein kinase-activated protein 
kinase 2 (MAPKAPK-2 or MK-2) is an important enzyme 
in signal transduction pathway controlling several path-
ways in cell proliferation [39]. MK-2 inhibition is one of 
the strategies of discovering new anticancer agents [40]. 
Recently, several urea and thiourea derivatives have 
shown good inhibitory activity on MK-2 [41]. Based 
on the thiourea scaffold of our newly synthesized com-
pounds and as a trial to suggest a mechanism of action 
for their cytotoxic activity, molecular docking was per-
formed on the active site of MK-2 for the most active 
compound. The protein data bank file (PDB:3WI6). The 
file contains MK-2 enzyme co-crystalized with an inhibi-
tor. All docking procedures were achieved by MOE 
(Molecular Operating Environment) software 10.2008 
provided by chemical computing group, Canada. The 
inhibitor interacts with MK-2 active site with four hydro-
gen bonds involving Glu 190, Leu 141, Asn 191 ans 
Asp 207 (Fig.  1). The docking protocol was validated 
by redocking of the ligand on the active site of MK-2 
enzyme with energy score (S) = −15.4978 kcal mol−1 and 
root mean square deviation (RMSD) = 1.1457.
The active compounds were docked on the active site 
of MK-2 using the same docking protocol. Energy scores 
and amino acid interactions were displayed in Table 2.
All the docked compounds were fit on the active site of 
MK-2 with energy scores ranging between −10.2371 and 
−20.1443  kcal  mol−1. Best docking score was exhibited 
by compound 16 which interacted with Lys 188 with one 
hydrogen bond (Fig. 2) while the best amino acid interac-
tion was exhibited by compound 3 which interacted with 
Leu 141 by two hydrogen bonds and Asp 207 with one 
hydrogen bond (Figs. 3, 4). The same previous two amino 
acids interacted also with the co-crystalized inhibitor in a 
comparable manner.  
Experimental
General chemistry
Melting points (uncorrected) were and determined in 
open capillary on a Gallen Kamp melting point appara-
tus (Sanyo Gallen Kamp, UK). Precoated silica gel plates 
(Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used 
for thin layer chromatography. A developing solvent 
system of chloroform/methanol (8:2) was used and the 
spots were detected by ultraviolet light. IR spectra (KBr 
disc) were recorded using an FT-IR spectrophotometer 
(Perkin Elmer, USA). 1H-NMR spectra were scanned on 
an NMR spectrophotometer (Bruker AXS Inc., Switzer-
land), operating at 500 MHz for 1H- and 125.76 MHz for 
Table 1 In vitro anticancer screening of the newly synthe-














 2 99.59 NA 148.33 NA
 3 29.12 35.63 39.83 26.28
 4 NA NA NA NA
 5 NA NA NA NA
 6 87.72 80.65 NA 64.56
 7 NA NA NA NA
 8 82.25 78.47 91.17 69.04
 9 55.08 42.16 66.27 38.46
 10 85.11 85.11 98.24 39.13
 11 NA NA NA NA
 12 NA NA NA NA
 13 NA NA NA NA
 14 NA NA NA NA
 15 74.75 93.42 NA 53.06
 16 114.28 NA NA 64.71
 17 NA NA NA NA
 DCF 124.87 54.07 114.12 113.94
 Doxoru-
bicin
164.46 70.01 217.15 15.41
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13C. Chemical shifts are expressed in δ-values (ppm) rela-
tive to TMS as an internal standard, using DMSO-d6 as a 
solvent. Elemental analyses were done on a model 2400 
CHNSO analyser (Perkin Elmer, USA). All the values 
were within ±0.4 % of the theoretical values. All reagents 
used were of AR grads.
Synthesis of thioureidobenzenesulfonamide derivatives 
(3–17)
General procedure
A mixture of 4-isothiocyanatobenzenesulfonamide 
2 (2.14  g, 0.01  mol) and amines (0.012  mol) in dry 




























Fig. 1 a YH345, b Indisulam, c general structure for the designed compounds
Table 2 Binding scores and  amino acid interactions of  the docked compounds on  the active site of  mitogen activated 
kinase (MK-2)
Compound no. S Kcal mol−1 Amino acid interactions Interacting groups Type of interaction H bond length Å
3 −15.4739 Leu 141 NH2 H‑bond (donor) 1.41
SO2 H‑bond (acceptor) 2.96
Asp 207 NH H‑bond (donor) 2.16
6 −13.1926 Lys 188 SO2 H‑bond (acceptor) 2.58
8 −17.6042 Lys 188 SO2 H‑bond (acceptor) 2.56
9 −10.2371 Asp 207 NH2 H‑bond (donor) 1.70
10 −18.9455 Glu 145 NH H‑bond (donor) 1.49
NH H‑bond (donor) 1.85
Lys 188 SO2 H‑bond (acceptor) 3.02
15 −13.5639 Lys 188 SO2 H‑bond (acceptor) 2.33
Asp 207 NH H‑bond (donor) 2.22
16 −20.1443 Lys 188 SO2 H‑bond (acceptor) 2.61
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triethylamine was refluxed for 24 h, then left to cool. The 
solid product formed upon pouring onto ice/water was 
collected by filtration and recrystallized from ethanol–
dimethylformamide to give 3–17, respectively.
4‑(3‑Heptylthioureido)benzenesulfonamide (3)
Yield, 92  %; m.p. 124.7  °C. IR (KBr, cm−1): 3218, 3143 
(NH, NH2), 3087 (CH arom.), 2926, 2853 (CH aliph.), 
1376, 1150 (SO2), 1254 (C=S). 1H-NMR (DMSO-d2): 
0.8 [t, 2H, CH3], 1.2–1.4 [m, 10H, 5CH2], 3.3 [m, 2H, 
NHCH2], 7.3–7.9 [m, 6H, Ar–H  +  SO2NH2], 9.3, 10.4 
[2  s, 2NH, exchangeable with D2O]. 13C-NMR (DMSO-
d6): 14.2, 22.4, 26.2, 28.6, 29.0, 31.5, 43.9, 119.4 (2), 127.4 
(2), 134.7, 143.0, 177.4.MS m/z (%): 329 (M+) (14.41), 155 
(100). Anal.Calcd. For C14H23N3O2S2 (329): C, 51.03; H, 
7.04; N, 12.75. Found: C, 51.29; H, 6.79; N, 12.45.
4‑(3‑(4‑Hydroxyphenyl)thioureido)benzenesulfonamide (4)
Yield, 88  %; m.p.192.9  °C. IR (KBr, cm−1): 3363 (OH), 
3280, 3143 (NH, NH2), 3090 (CH arom.), 1393, 1182 
(SO2), 1274 (C=S).1H-NMR (DMSO-d2): 6.7–7.9 [m, 
10H, Ar–H  +  SO2NH2], 10.2, 11.4, [2  s, 2H, 2NH, 
exchangeable with D2O], 13.1 [s, 1H, OH, exchangeable 
with D2O], 13C-NMR (DMSO-d6): 112.9 (2), 122.8 (2), 
126.7 (2), 127.1 (2), 127.9, 139.8, 140.3, 157.6, 180.1. 
MS m/z (%): 323 (M+) (9.03), 91 (100). Anal.Calcd. For 
C13H13N3O3S2 (323): C, 48.28; H, 4.05; N, 12.99. Found: 
C, 48.55; H, 4.31; N, 13.29.
4‑(3‑(3,5‑Dimethoxyphenyl)thioureido)benzenesulfonamide 
(5)
Yield, 77  %; m.p. 160.3  °C. IR (KBr, cm−1): 3317, 3254, 
3173 (NH, NH2), 3100 (CH arom.), 2963, 2938, 2829 
(CH aliph.), 1363, 1156 (SO2), 1259 (C=S). 1H-NMR 
(DMSO-d2): 3.9 [s, 6H, 2OCH3], 6.3–7.8 [m, 8H, 
Ar–H  +  SO2NH2], 9.8 [s, 2H, 2NH, exchangeable with 
D2O].13C-NMR (DMSO-d6): 56.1 (2), 96.8, 102.0 (2), 
123.2 (2), 126.6 (2), 141.4 (2), 143.1, 160.6 (2), 179.3. 
MS m/z (%): 367 (M+) (17.8), 76 (100). Anal.Calcd. For 
C15H17N3O4S2 (367): C, 49.03; H, 4. 66; N, 11.44. Found: 
C, 48.74; H, 4.29; N, 11.17.
4‑(3‑(2‑Methyl‑6‑nitrophenyl)thioureido)
benzenesulfonamide (6)
Yield, 81  %; m.p. 226.0  °C. IR (KBr, cm−1): 3353, 3243, 
3171 (NH, NH2), 3009 (CH arom.), 1340, 1161 (SO2), 
Fig. 2 Co‑crystalized lignd in the active site of mitogen activated kinase (MK‑2)
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1290 (C=S).1H-NMR (DMSO-d2): 2.2 [s, 3H, CH3], 
6.5–7.8 [m, 9H, Ar–H  +  SO2NH2], 10.3 [s, 2H, 2NH 
exchangeable with D2O]. 13C-NMR (DMSO-d6): 18.3, 
123.3, 123.9 (2), 126.7, 126.8, 127.8 (2), 131.3, 136.5 (2), 
139.8, 142.8, 180.1. MS m/z (%): 366 (M+) (15.8), 133 
(100). Anal.Calcd. For C14H14N4O4S2 (366): C, 45.89; H, 
3.85; N, 15.29. Found: C, 45.57; H, 3.54; N, 15.61.
4‑(3‑Benzo[d][1,3]dioxol‑5‑ylthioureido)benzenesulfonamide 
(7)
Yield, 86  %; m.p. 136.6  °C. IR (KBr, cm−1): 3325, 3241 
(NH, NH2), 3100 (CH arom.), 1331, 1156 (SO2), 1241 
(C=S). 1 H-NMR (DMSO-d2): 6.0 [s, 2H, CH2], 6.7–7.9 
[m, 9H, Ar–H + SO2NH2], 9.5 [s, 2H, 2NH, exchangeable 
with D2O]. 13C-NMR (DMSO-d6): 101.2, 107.1, 109.1, 
117.8, 123.1 (2), 126.5 (2), 133.4, 134.6, 142.4, 143.2, 
147.3, 180.6. MS m/z (%): 351 (M+) (34.64), 93 (100). 
Anal.Calcd. For C14H13N3O4S2 (351): C, 47.85; H, 3.73; N, 
11.96. Found: C, 47.49; H, 3.43; N, 11.62.
4‑(3‑Benzo[d][1,3]dioxol‑5‑ylmethyl)thioureido)
benzenesulfonamide (8)
Yield, 68  %; m.p. 140.8  °C. IR (KBr, cm−1): 3384, 3348, 
3206 (NH, NH2), 3003 (CH arom.), 1377, 1185 (SO2), 
1294 (C=S).1H-NMR (DMSO-d2): 4.3 [s, 2H, CH2], 6.0 [s, 
2H, OCH2O], 6.7–7.7 [m, 9H, Ar–H + SO2NH2], 7.8 [s, 
2H, +2NH, exchangeable with D2O]. 13C-NMR (DMSO-
d6): 63.8, 101.2, 106.4, 108.2, 120.8, 121.4 (2), 131.2 (2), 
133.5, 134.0, 146.4, 147.6, 148.3, 161.1. MS m/z (%): 365 
(M+) (18.42), 135 (100). Anal.Calcd. For C15H15N3O4S2 
(365): C, 49.30; H, 4.14; N, 11.50. Found: C, 49.05; H, 
4.46; N, 11.19.
4‑(3‑(1‑Adamanylamine)thioureidobenzenesulfonamide (9)
Yield, 80  %; m.p. 174.5  °C. IR (KBr, cm−1): 3434, 3354 
(NH, NH2), 3100 (CH arom.), 2997, 2906, 2851 (CH 
aliph.), 1396, 1186 (SO2), 1282 (C=S).1H-NMR (DMSO-
d2): 1.6–1.9 [m, 12H, 6CH2], 2.2–2.4 [m, 3H, 3 CH], 
6.9–7.9 [m, 6H, Ar–H  +  SO2NH2], 11.4 [s, 2H, 2NH, 
exchangeable with D2O].13C-NMR (DMSO-d6): 28.8 (3), 
35.3 (3), 40.5 (3), 44.9, 126.4 (2), 129.1 (2), 131.8, 142.7, 
179.9. MS m/z (%): 366 (M+) (9.32), 154 (100). Anal.
Calcd. For C17H23N3O2S2 (366): C, 55.86; H, 6.34; N, 
11.50. Found: C, 55.50; H, 6.68; N, 11.18.
4‑(3‑(5,6‑Dimethylbenzo[d]thiazol‑2‑yl)thioureido)
benzenesulfonamide (10)
Yield, 84  %; m.p. 252.1  °C. IR (KBr, cm−1): 3359, 
3257, 3143 (NH, NH2), 3031 (CH arom.), 2954, 2851 
(CH aliph.), 1594 (C=N), 1381, 1186 (SO2), 1296 
Fig. 3 Compound 16 in the active site of mitogen activated kinase (MK‑2)
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(C=S).1H-NMR (DMSO-d2): 2.2 [s, 6H, 2CH3], 7.2–8.0 
[m, 8H, Ar–H  +  SO2NH2], 10.2, 13.0 [2  s, 2H, 2NH, 
exchangeable with D2O].13C-NMR (DMSO-d6): 19.9, 
20.4, 118.5, 121.5, 123.3 (2), 126.6, 127.1, 127.8 (2), 133.0, 
136.2, 139.8, 143.1, 151.9, 180.0 (2).MS m/z (%): 393 (M+) 
(16.9), 162 (100). Anal.Calcd. For C16H16N4O2S3 (393): 




Yield, 78  %;m.p. 153.6  °C. IR (KBr, cm−1): 3410, 3334, 
3195 (NH, NH2), 3069 (CH arom.), 2974, 2925, 2843 (CH 
aliph.), 1595 (C=N), 1393, 1123 (SO2), 1256 (C=S). 1H-
NMR (DMSO-d2): 1.3 [t, 3H, CH3], 4.0 [q, 2H, CH2], 6.9–
8.0 [m, 9H, Ar–H + SO2NH2], 10.3, 11.2 [2 s, 2H, 2NH, 
exchangeable with D2O]. 13C-NMR (DMSO-d6): 15.0, 
66.8, 106.0, 115.3, 118.2, 120.4 (2), 127.7 (2), 132.7, 138.2, 
140.9, 142.1, 157.7, 177.1, 180.1. MS m/z (%): 409 (M+) 
(1.85), 156 (100). Anal.Calcd. For C16H16N4O3S3 (409): C, 
47.04; H, 3.95;N, 13.71. Found: C, 47.34; H, 3.67; N, 13.39.
4‑(3‑(6‑Nitrobenzo[d]thiazol‑2‑yl))thioureido)
benzenesulfonamide (12)
Yield, 65  %; m.p. 205.8  °C. IR (KBr, cm−1): 3384, 3261, 
3165 (NH, NH2), 3097 (CH arom.), 1595 (C=N), 1331, 
1185 (SO2), 1252 (C=S).1H-NMR (DMSO-d2): 7.1–8.9 
[m, 9H, Ar–H  +  SO2NH2], 10.5, 12.0 [2  s, 2H, 2NH, 
exchangeable with D2O]. 13C-NMR (DMSO-d6): 119.6 
(2), 123.1 (3), 126.6 (3), 139.8 (2), 142.8, 161.2179.9 (2). 
MS m/z (%): 409 (M+) (13.43), 178 (100). Anal.Calcd. For 
C14H11N5O4S3 (409): C, 41.07; H, 2.71; N, 17.10. Found: 
C, 41.31; H, 2.40; N, 17.43.
4‑(3‑(5‑(Bromopyridin‑2‑yl)thioureido)benzenesulfonamide 
(13)
Yield, 72  %; m.p. 247.0  °C. IR (KBr, cm−1): 3326, 3175 
(NH, NH2), 3088 (CH arom.), 1572 (C=N), 1356, 1192 
(SO2), 1211 (C=S). 1H-NMR (DMSO-d2): 6.8–8.3 [m, 
8H, Ar–H +  SO2NH2], 12.4 [s, 2H, 2NH, exchangeable 
with D2O]. 13C-NMR (DMSO-d6): 105.5, 124.8 (2), 128.9 
(2), 134.6, 140.8, 158.5, 159.3 (2), 178.6.MS m/z (%): 388 
(M+) (11.81), 157 (100). Anal.Calcd. For C11H10BrN5O2S2 
Fig. 4 Compound 3 in the active site of mitogen activated kinase (MK‑2)
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(388): C, 34.03; H, 2.60; N, 18.04. Found: C, 34.28; H, 
2.27; N, 18.37.
4‑(3‑Pyrazin‑2‑ylthioureido)benzenesulfonamide (14)
Yield, 80  %; m.p. 185.3  °C. IR (KBr, cm−1): 3378, 3240, 
3155 (NH, NH2), 3100 (CH arom.), 1601 (C=N), 1346, 
1199 (SO2), 1270 (C=S).1H-NMR (DMSO-d2): 7.2–8.7 
[m, 9H, Ar–H  +  SO2NH2], 11.3, 13.0 [2  s, 2H, 2NH, 
exchangeable with D2O]. 13C-NMR (DMSO-d6): 123.1 
(2), 126.7 (2), 137.1, 138.4, 138.5, 139.9, 140.3, 149.7, 
179.0. MS m/z (%): 309 (M+) (12.83), 79 (100). Anal.
Calcd. For C11H11N5O2S2 (309): C, 42.71; H, 3.58; N, 
22.64. Found: C, 42.38; H, 3.84; N, 22.29.
4‑(3‑(5,6,7,8‑Tetrahydronaphthalen‑1‑yl)thioureido)
benzenesulfonamide (15)
Yield, 76  %; m.p. 171.8  °C. IR (KBr, cm−1): 3413, 3354, 
3152 (NH, NH2), 3083 (CH arom.), 2982, 2935, 2831 
(CH aliph.), 1351, 1159 (SO2), 1264 (C=S).1H-NMR 
(DMSO-d2): 1.8–2.8 [m, 8H, 4CH2, cyclo], 7.0–8.0 
[m, 9H, Ar–H +  SO2NH2], 9.0[s, 2H, 2NH, exchange-
able with D2O]. 13C-NMR (DMSO-d6): 22.7 (2), 24.8, 
29.6, 117.4, 120.8 (2), 124.0, 125.7, 127.4 (2), 134.5, 
137.1, 137.4, 137.6, 146.4, 181.5.MS m/z (%): 361 (M+) 
(26.34), 177 (100). Anal.Calcd. For C17H19N3O2S2 (361): 
C, 56.48; H, 5.30; N, 11.62. Found: C, 56.12; H, 5.03; N, 
11.36.
4‑(3‑Quinolin‑3‑ylthioureido)benzenesulfonamide (16)
Yield, 66  %; m.p. 214.6  °C. IR (KBr, cm−1): 3373, 3246, 
3164 (NH, NH2), 3077 (CH arom.), 1595 (C=N), 1365, 
1150 (SO2), 1293 (C=S). 1H-NMR (DMSO-d2): 6.8–8.5 
[m, 12H, Ar–H + SO2NH2], 10.8 [s, 2H, 2NH, exchange-
able with D2O].13C-NMR (DMSO-d6): 127.3, 127.7, 
128.6, 129.1 (2), 130.0 (2), 132.0, 134.3 (2), 137.9 (2), 
142.8, 178.6. MS m/z (%): 358 (M+) (17.53), 156 (100). 
Anal.Calcd. For C16H14N4O2S2 (358): C, 53.61; H, 3.94; N, 
15.63. Found: C, 53.36; H, 3.62; N, 15.36.
4‑(3‑(2‑Methylquinolin‑4‑yl)thioureido)benzenesulfonamide 
(17)
Yield, 71  %; m.p. 192.3  °C. IR (KBr, cm−1): 3363, 3218, 
3154 (NH, NH2), 3034 (CH arom.), 2943, 2836 (CH 
aliph.), 1590 (C=N), 1324, 1154 (SO2), 1241 (C=S). 1H-
NMR (DMSO-d2): 2.6 [s, 3H, CH3], 6.6–8.8 [m, 11H, 
Ar–H  +  SO2NH2], 10.1, 13.8[2  s, 2H, 2NH, exchange-
able with D2O]. 13C-NMR (DMSO-d6): 19.9, 102.0, 108.3, 
121.1 (2), 122.9, 124.0, 126.1, 127.8, 128.0 (2), 137.3, 
139.5, 143.1, 151.7, 158.0, 179.3. MS m/z (%): 372 (M+) 
(21.22), 141 (100). Anal.Calcd. For C17H16N4O2S2 (372): 
C, 54.82; H, 4.33; N, 15.04. Found: C, 54.51; H, 4.09; N, 
15.31.
In vitro anticancer evaluation
Cell culture
Human cancer cell lines HeLa (cervical), A549 (lungs) 
and Lovo (colorectal) were grown in DMEM + GlutaMax 
(Invitrogen), and MDA MB321 (breast) were grown in 
DMEM-F12 + GlutaMax) medium (invitrogen), supple-
mented with 10 % heat-inactivated bovine serum (Gibco) 
and 1× penicillin–streptomycin (Gibco) at 37  °C in a 
humified chamber with 5 % CO2 supply.
Cytotoxicity assay
The in  vitro anticancer screening was done at pharma-
cognosy Department, College of Pharmacy, King Saud 
University, Riyadh, Saudi Arabia. Cells were seeded (105 
cells/well) in 96-well flat-bottom plates (Becton–Dick-
inson Labware) a day before treatment and grown over-
night. Compounds were dissolved in dimethyl sulfoxide 
(DMSO; Sigma) and finally prepared as 1.0  mg  ml−1 
stocks, respectively in the culture media. The final con-
centration of DMSO never exceeded 0.1  % in the treat-
ment doses. Four different doses of compounds (50, 25, 
12.5 and 6.25  µg  ml−1) were further prepared by dilut-
ing the stocks in culture media, and cells were treated 
(in triplicate/dose). 2′7′ dichlorofluorescein (DCF) was 
included as standard reference drug (positive control) 
and untreated culture was considered as negative con-
trol. The treated cultures were further incubated for 48 h. 
At 48 h post-treatment, cell viability test was performed 
using TACS MTT Cell Proliferation and Viability Assay 
Kit (TACS) as per manufacturer’s instructions. The opti-
cal density (OD) was recorded at 570 nm in a microplate 
reader (BioTek, ELx800) and cell survival fraction was 
determined. The cell survival fraction was calculated 
as [(A − B)/A], where A and B are the OD of untreated 
and of treated cells, respectively [42]. The IC50 values of 
the tested compound were estimated using the best fit 
regression curve method in Excel.
Microscopy
A direct visual investigation was made under an inverted 
microscope (Optica, 40× and 100×) to observe any mor-
phological changes in the cells cultured with different 
treatment doses at 24 and 48 h.
Molecular docking
All the molecular modeling studies were carried out on 
an Intel Pentium 1.6  GHz processor, 512  MB memory 
with Windows XP operating system using Molecular 
Operating Environment (MOE, 10.2008) software. All the 
minimizations were performed with MOE until a RMSD 
gradient of 0.05 kcal mol−1 Å with MMFF94X force field 
and the partial charges were automatically calculated. 
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The protein data bank file (PDB: 3WI6) was selected for 
this purpose. The file contains MK-2 enzyme co-crys-
talized with a ligand obtained from protein data bank. 
The enzyme was prepared for docking studies where: (1) 
Ligand molecule was removed from the enzyme active 
site. (2) Hydrogen atoms were added to the structure 
with their standard geometry. (3) MOE Alpha Site Finder 
was used for the active sites search in the enzyme struc-
ture and dummy atoms were created from the obtained 
alpha spheres. (4). The obtained model was then used in 
predicting the ligand enzymes interactions at the active 
site.
Conclusions
In summary, we had synthesized a novel series of sul-
fonamide thiourea derivatives. Seven compounds 3, 6, 8, 
9, 10, 15 and 16 showed good anticancer activity against 
lung (A594 Raw), Hela, and Colorectal (Lovo) cancer cell 
lines with better or comparable activity to DCF. Moreo-
ver, molecular docking for these active compounds 
showed proper fitting on the active site of MK-2 enzyme 
suggesting their action as inhibitors for this enzyme but 
more investigation should be carried out in the future to 
explore precisely the mechanism of the action of the syn-
thesized derivatives.
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